A Study of LY3971297 in Participants With Heart Failure

← catalyst calendar

NCT07547540 · readout ≤ 468 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

90estimated

Sites

Countries

Japan, Moldova, Netherlands +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Aug 2026

estimated

When the study began enrolling

Primary completion

Nov 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Nov 2027

estimated

The whole study's end, after follow-up

First posted

2026-04-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Heart Failure
Heart Failure, Diastolic
Heart Failure, Systolic

Interventions

Drug: LY3971297
Drug: LY3971297
Drug: Placebo
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

measured Baseline through Study Completion (Approximately 2 Months)

Number of Participants with One or More Treatment-Emergent Adverse Event

measured Baseline through Study Completion (Approximately 2 Months)

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed